Articles related to STIMULANTS

The FDA issued a Class II recall for an amphetamine-based ADHD medication after a labeling mix-up resulted in immediate-release capsules being packaged as extended release. The recall affects a single lot totaling 1,392 bottles.

Primary care physicians increasingly inherit adult ADHD stimulant prescriptions amid specialist shortages and medication supply disruptions. Expert guidance highlights diagnostic verification, monitoring, and risk-assessment considerations without establishing a single standardized approach.

Youth with ADHD and comorbid ASD showed distinct medication patterns and greater psychiatric burden in a large EHR cohort. The observational findings did not establish causal treatment effects.

A psychiatric mental health NP outlined clinical and regulatory safeguards for virtual ADHD stimulant prescribing, noting that federal telehealth flexibilities extending through December 2026 do not supersede stricter state-level requirements.

“Additional research is needed to determine whether the modest elevations in suicidal behavior observed during treatment are due to true medication effects or to persistence in the distress that prompted treatment initiation.” — Study authors, Biological Psychiatry Global Open Science

“Essentially, we found that stimulants pre-reward our brains and allow us to keep working at things that wouldn’t normally hold our interest.” – Dr. Nico Dosenbach, Washington University School of Medicine